The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. - Wikidata - wikimedia - TriplyDB

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.

http://www.wikidata.org/entity/Q34118020

about

Efficacy and safety of vardenafil in men with diabetes and erectile dysfunction Efficacy and safety of vardenafil in men with diabetes and erectile dysfunction Conformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and Sildenafil Potency, selectivity, and consequences of nonselectivity of PDE inhibition PDE5 is converted to an activated state upon cGMP binding to the GAF A domain Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events.PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis.Chuanxiongzine relaxes isolated corpus cavernosum strips and raises intracavernous pressure in rabbits.Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.T-1032, a cyclic GMP phosphodiesterase-5 inhibitor, acutely blocks physiologic insulin-mediated muscle haemodynamic effects and glucose uptake in vivo.The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases The effects of tadalafil on renal ischemia reperfusion injury: an experimental study.Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases.New achievements and pharmacotherapeutic approaches to impotence in the elderly.Vardenafil treatment for erectile dysfunction.Implications of PDE4 structure on inhibitor selectivity across PDE families.Therapeutic strategies for optimizing PDE-5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat.Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility.Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports.Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy.PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.Potency and selectivity of vardenafil: a phosphodiesterase Type 5 inhibitor.The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy.Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction.Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study.Role of phosphodiesterase 5 in synaptic plasticity and memory Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters.Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors.Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil.Erectile dysfunction drugs and oxidative stress in the liver of male rats Pharmacophore elucidation and molecular docking studies on phosphodiesterase-5 inhibitors.Effect of sildenafil on platelet function and platelet cGMP of patients with erectile dysfunction.Effects of vardenafil on testicular torsion/detorsion damage: an experimental study in pigs.Effects of tetrandrine on cAMP and cGMP levels in rabbit corpus cavernosum in vitro.Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.

P2860

Q24236046-6F885B0A-8F31-45E8-98D0-CBF1E210813C Q24240809-DD3F73B8-56BD-4F97-A916-D3234766F7F0 Q27648887-05613D45-D7B7-4CEC-97CE-FBE99FCDB0D3 Q28269129-7238D0D9-014C-4985-8C37-B7F24F38904A Q28593893-220AD73F-3737-40A2-AF42-5C33429C0882 Q30940197-1CA1A74E-9BBC-4AA0-A501-266168EDC8D0 Q33348441-EA8CA2F1-1502-4048-AA5D-425CCED33B90 Q33710353-4C9ED28E-3DA1-47AE-ACA6-5C1A116923BD Q34498198-B04DE6A5-8508-4147-8151-70D92435BAFA Q35045921-3BEA3F28-7E5C-440A-9509-7D0F54FFE433 Q35156618-AE8C7001-9BA9-49B8-8405-CDE412CC940E Q35184655-573C4B85-71A3-4E1F-8257-E4D0B55B47C3 Q35500693-4C1F34F5-A137-4C2D-90D6-EDC8D809B802 Q35569842-F83FE2FB-16F3-47D2-BE4E-9291F4D7008A Q35638042-77B724DE-E2E7-4744-8062-5F778E338D2A Q35821270-37FF9E71-ED30-4D09-AA91-7A59053589AC Q35821281-FEA8FB1A-7C0D-4F9A-9CAD-DA5EEDC25193 Q35824102-A31A9E22-AC54-466F-AF5F-C6F974E15157 Q35824111-D07AC963-CAF7-4D6E-8A61-81D5C05B6A78 Q36069701-55FDA1A7-6028-4FFA-876D-A36213C8EA68 Q36124056-2E669528-756C-40BB-8BDB-0B76E9E8704D Q36334968-C13FBBC7-B302-4E1A-8DF4-7099A37D61A1 Q36357896-CCC211A1-C9AC-4811-AC17-FAECCA69752D Q36395193-E9EEC3E7-C522-4921-A3A6-E0210E91EB86 Q36572595-27425A05-C601-4E9D-82E7-F22BC840B9DF Q36599937-56385638-9C86-4AB4-BBAF-459119DE529C Q36689825-25E7CAEF-92BA-4E0B-ADB2-9C4FDA61A8B2 Q36808042-7A575178-699A-4A20-A40E-B3CE4FEF3045 Q37250597-968D235C-CDDB-4864-9D0F-EBCDDE214ED8 Q37252748-BD0BF418-0BC9-4558-B2FC-77DD5B23289C Q38052592-A400114E-FBDD-4B13-B81C-F4DA3D76CA9C Q38815890-29123371-8B25-4B6D-A50D-50C2D1416EF7 Q39072124-FD90BF34-3E6E-4617-962C-738EF9AA37FE Q40352545-74EAFD38-D5D7-4AC5-B9FD-9FDF3014BCD6 Q41680225-9D7A81D8-DCCC-4D23-BCF7-F4D913BBB122 Q42007717-41ADCB5A-2896-422E-9B80-496C9BA22CAB Q42469987-9902830F-9537-4D57-A0EA-82991C36FB83 Q42480674-4CAD42F4-1CCB-4B24-8E8A-F3EFB2F1ED24 Q43003792-230AA67E-0530-48AF-9839-B70979F14B09 Q44257745-D998DADC-052D-4CA4-86D3-DFF6C5A8AE1E

P2860

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.

http://www.wikidata.org/entity/Q34118020

description

2001 nî lūn-bûn

@nan

2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@ast

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@en

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@nl

type

label

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@ast

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@en

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@nl

prefLabel

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@ast

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@en

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@nl

P1433

Q34118020-E81A4573-6DA0-4446-B415-E57BD608344D

P1476

Q34118020-84F970CE-6789-4C97-A7FF-D0C1BA142D72

P2093

Q34118020-26D466BE-E8A8-4C7E-9750-F733AF40B010

Q34118020-54EC71DC-299F-4085-8D47-479D2CB43D00

Q34118020-6BA1468D-0251-4176-98D0-001E46749E6B

Q34118020-6EA04C73-BC48-417B-8AB2-212AA0F66D85

Q34118020-711AB64F-52A0-42B3-9101-4FA2433501C4

Q34118020-7B78DF94-4656-4580-8259-A7C4CDF205DD

Q34118020-7BEAD574-3E2D-4F26-B7EA-DFD89E53E5CA

Q34118020-A8E2AD64-4D36-44EC-B5BD-1C16B0F1BE68

Q34118020-C5EB1EE5-8F4A-44B4-B4DA-5A60EC6655E6

Q34118020-D6D82847-C4D6-4F3A-961D-238D37DA407E

P2888

Q34118020-38EECBAC-0ED9-498C-BAD9-A092DBF7E612

P304

Q34118020-87E4BDD3-DC10-4C72-83E8-3069654D480C

P31

Q34118020-63C12320-5508-4B40-9A55-EE71EE29D5C9

P356

Q34118020-5214F716-F44E-46A0-8DD5-CF9DAC5FF166

P433

Q34118020-FFECACC1-01F9-4F4F-BD0E-AC8C5D8FD06E

P478

Q34118020-1161F9BF-A77F-47CA-8D87-B0814ABE161B

P577

Q34118020-20E40B1B-4321-4EEE-8214-4F1DC8E71B2F

P5875

Q34118020-AD419B1F-776F-466D-8985-7DF0FC683460

P6179

Q34118020-DE9C4CA4-D045-459B-9EA5-018B8C1B5679

P698

Q34118020-BB6542EB-E80D-422B-B731-E70A7C8F8E54

P356

SJ.IJIR.3900726

P1433

International Journal of Impotence Research

P1476

The phosphodiesterase inhibito ...... new PDE5 inhibitor vardenafil.

@en

P2093

Allona A

http://www.w3.org/2001/XMLSchema#string

Angulo J

http://www.w3.org/2001/XMLSchema#string

Bischoff E

http://www.w3.org/2001/XMLSchema#string

Cuevas P

http://www.w3.org/2001/XMLSchema#string

Fernández A

http://www.w3.org/2001/XMLSchema#string

Haning H

http://www.w3.org/2001/XMLSchema#string

Körschen HG

http://www.w3.org/2001/XMLSchema#string

Lledó E

http://www.w3.org/2001/XMLSchema#string

Moncada I

http://www.w3.org/2001/XMLSchema#string

Niewöhner U

http://www.w3.org/2001/XMLSchema#string

P2888

sj.ijir.3900726

P304

282-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.IJIR.3900726

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11471890

http://www.w3.org/2001/XMLSchema#string

P6179

1037765808

http://www.w3.org/2001/XMLSchema#string

P698

11890515

http://www.w3.org/2001/XMLSchema#string